Wearable Injectors and Connected Devices
Wearable Injectors and Connected Devices
6th October to 7th October 2021,
London, United Kingdom
SMi's 2nd Annual Conference
Wearable Injectors and Connected Devices
6 - 7 October, 2021 | London
The global wearable devices market size is expected to reach a value of $62.82 billion USD by 2025 with time dependent delivery, improved patient experience and adherence and large volume administration with minimal injection pain and being key factors driving the market.
With that in mind, SMi is proud to present Europe's only Wearable Injectors Conference, taking place on the 6th-7th of October 2021, in London.
SMi’s 2nd annual Wearable Injectors and Connected Devices conference will explore real world examples of on-body device design and development for large volume delivery while engaging in the latest digital applications for wearable devices with industry case studies from pharma thought leaders. Assess the potential of connectivity and software for medical devices in this year’s packed agenda and understand how this is aiding the use of wearable devices for clinical trials. Furthermore, key regulatory updates and guidance will be presented by regulatory, notified body and industry experts for a comprehensive outlook of this exciting and ever-growing field.
This two-day agenda offers you peer-to-peer networking with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.
We look forward to welcoming you to the conference in October.
source: http://www.smi-online.co.uk/pharmaceuticals/uk/conference/wearable-injectors
If you have any questions about this news, please do not hesitate to contact us.
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE